Japan Asia Investment Corporation
2F Medical Friend Building, 3-2-4 Kudankita, Tokyo, Chiyoda-ku, 102-0073, Japan
Overview
JAIC is Japan's largest independent venture capital firm and has accumulated experience and know-how over a period of 15 years as a pioneer of venture capital investments in Asia. Building on such strengths, they are establishing a globally linked organization that pursues investment opportunities centering on the three regions of Japan, Asia, and the United States.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Business Development
- Financial Services
- Venture Capital
- Web Hosting
Investment portfolio
- REGiMMUNE
Led · Series D · Feb 2014
Regimmune focuses on discovery, development and commercialization of immune regulatory therapeutics to treat allergies, autoimmune diseases and complications of transplantation. Its proprietary reVax platform induces immune tolerance in an antigen-specific manner via pharmacological induction of regulatory T (Treg) cells. The company completed a Phase I study of RGI-2001 for graft-versus-host disease and has initiated a Phase II trial of RGI-2001. Regimmune is developing multiple pipeline programs including the RGI-1000 series for allergy, the RGI-3100 series for type 1 diabetes, products to prevent inhibitor formation in enzyme replacement therapies, and a celiac disease program with undisclosed partners. Led by Haru Morita, the company has operations in Tokyo and a US presence in San Francisco. It intends to use the proceeds from the recent financing to support early-stage product development.
Team
No current team members are available.